Read by QxMD icon Read

Clinical Colorectal Cancer

Grace G Wong, Vincent Ha, Michael P Chu, Deonne Dersch-Mills, Sunita Ghosh, Carole R Chambers, Michael B Sawyer
BACKGROUND: First-line adjuvant chemotherapy options for early-stage colorectal cancer (CRC) include CapeOx (capecitabine, intravenous oxaliplatin) and FOLFOX (intravenous 5-fluorouracil, leucovorin, oxaliplatin). Capecitabine is an oral prodrug analog of 5-fluorouracil, and recent studies have suggested that proton pump inhibitors (PPIs) may detrimentally affect capecitabine efficacy. Conversely, some literature suggests that PPIs may negatively affect CRC itself. To gain insight into the nature of PPIs' effect on capecitabine and CRC, we investigated their effects on effectiveness of CapeOx versus FOLFOX chemotherapy...
November 16, 2018: Clinical Colorectal Cancer
Omar Abdel-Rahman
BACKGROUND: 5-Fluorouracil (5-FU) represents the backbone of systemic therapy regimens of colorectal cancer. The current study aims at evaluating the patterns and predictors of cardiac adverse events associated with various 5-FU-based systemic therapy regimens among patients with metastatic colorectal cancer. MATERIALS AND METHODS: This pooled analysis includes de-identified patient-level datasets from 5 randomized studies (NCT00272051, NCT00305188, NCT00115765, NCT00364013, and NCT00384176)...
November 1, 2018: Clinical Colorectal Cancer
Yaqi Li, Yang Feng, Weixing Dai, Qingguo Li, Sanjun Cai, Junjie Peng
BACKGROUND: The prognostic value of tumor sidedness in metastatic colorectal cancer (CRC) has been established, but its impact on nonmetastatic disease remains unclear. Our study aimed to explore the prognostic effect of tumor sidedness by subgroup survival analyses, according to histology and tumor grade in stage I-IV CRCs. METHODS: A retrospective population-based study was conducted based on Surveillance, Epidemiology and End Results (SEER) data. Population data in the SEER 9 registry (1975-2014) were used to determine survival trends of CRCs, and associated population data in the SEER 18 registry (2000 to 2014) were used to assess the prognostic impact of tumor sidedness on CRCs...
October 27, 2018: Clinical Colorectal Cancer
Caroline Brenner Thomsen, Rikke Fredslund Andersen, Jan Lindebjerg, Torben Frøstrup Hansen, Lars Henrik Jensen, Anders Jakobsen
BACKGROUND: RAS and RAF mutations in colorectal cancer (CRC) hold value in precision medicine. Liquid biopsy is an alternative to tumor tissue biopsy, and circulating tumor DNA (ctDNA) has been intensively investigated, but the clinical relevance of RAS and RAF mutations in plasma is yet to be determined. This study aimed to investigate the clinical aspects of RAS/RAF mutations during combination treatment. PATIENTS AND METHODS: Patients with RAS/RAF tumor wild-type metastatic CRC treated with combination chemotherapy and an EGFR inhibitor were included...
October 24, 2018: Clinical Colorectal Cancer
Jaafar Bennouna, Thierry André, Loïc Campion, Sandrine Hiret, Laurent Miglianico, Laurent Mineur, Yann Touchefeu, Pascal Artru, Timothy Asmis, Olivier Bouché, Florence Borde, Petr Kavan, You-Heng Lam, Laetitia-Shana Rajpar, Jean-François Emile, Claire Jouffroy, Sharlene Gill, Julien Taïeb
BACKGROUND: According to the IDEA trial, 6-month adjuvant chemotherapy should remain the treatment standard in stage III T4 or N2 colon cancer. The relatively poor survival in this high-risk subgroup-a 3-year disease-free survival (DFS) rate of 65%-and the potential synergistic efficacy of 5-fluorouracil (5-FU), oxaliplatin, and irinotecan suggest that FOLFIRINOX may be a regimen of particular interest in this setting. PATIENTS AND METHODS: This multicenter international phase 3 trial (ClinicalTrials...
October 19, 2018: Clinical Colorectal Cancer
Pashtoon Murtaza Kasi, Faisal Shahjehan, Jordan J Cochuyt, Zhuo Li, Dorin Toma Colibaseanu, Amit Merchea
BACKGROUND: Recent trends have identified increasing number of young individuals with rectal and colon cancers. These individuals, who are younger than 50 years old, in most instances would not meet screening guidelines. We aimed to report the characteristics and trend of the rising proportion of young individuals being diagnosed with rectal and colon cancers at our institutions. PATIENTS AND METHODS: This study included 3381 rectal and colon cancer patients from the Mayo Clinic cancer registry from 1972 to 2017 who were diagnosed with rectal or colon cancer and who were < 50 years old...
October 17, 2018: Clinical Colorectal Cancer
Marianne Grønlie Guren, Bjarte Aagnes, Mari Nygård, Olav Dahl, Bjørn Møller
BACKGROUND: Anal squamous cell carcinoma (ASCC) is a rare, human papilloma virus-associated cancer. The purpose was to investigate the population-based incidence rates, age and gender distribution, and survival of ASCC. MATERIALS AND METHODS: All primary ASCC in 1987 to 2016 were identified in the Cancer Registry of Norway (N = 1548), with information on age, gender, stage, county of residence, radiotherapy, and survival. RESULTS: Median age was 66 years; 71% were females...
October 16, 2018: Clinical Colorectal Cancer
Irina Druzhkova, Nadezhda Ignatova, Natalia Prodanets, Nikolay Kiselev, Iliya Zhukov, Marina Shirmanova, Vladimir Zagainov, Elena Zagaynova
BACKGROUND: The conventional chemotherapy of colorectal cancer with irinotecan, 5-fluorouracil, and oxaliplatin remains one of the front-line treatments worldwide. However, its efficacy is quite low. Recently studies of the epithelial-mesenchymal transition (EMT) have become the focus of investigations into the cause of chemoresistance in several types of cancer, including colorectal cancer. The data about the role of EMT in chemosensitivity are controversial. MATERIALS AND METHODS: Human colon adenocarcinoma cell lines HT29 and HCT116 and 14 primary short-term cultures established from patient tumors were used...
October 16, 2018: Clinical Colorectal Cancer
Sakti Chakrabarti, Jaskanwal Sara, Ronstan Lobo, Rachel Eiring, Heidi Finnes, Jessica Mitchell, Mindy Hartgers, Akiko Okano, Thorvardur Halfdanarson, Axel Grothey
INTRODUCTION: Coronary vasospasm associated with fluoropyrimidine (FP)-based chemotherapy is a potentially serious complication and reported to occur more often with infusional 5-fluorouracil (5-FU) or capecitabine than with bolus 5-FU. Given the additional benefit of oxaliplatin over FP alone in the management of colorectal cancer, retaining oxaliplatin in the treatment regimen is desirable, but the safety of combining bolus 5-FU with oxaliplatin in patients with FP-induced vasospasm is not well established...
October 10, 2018: Clinical Colorectal Cancer
Khurum Khan, Jayant K Rane, David Cunningham, Sheela Rao, David Watkins, Naureen Starling, Eleftheria Kalaitzaki, Martin Forster, Chiara Braconi, Nicola Valeri, Marco Gerlinger, Ian Chau
BACKGROUND: Gastrointestinal (GI) cancer patients may not be considered for therapy with fluoropyrimidines (FPs) because of previous cardiovascular (CV) toxicity or preexisting risk factors; such patients may benefit from raltitrexed-based therapy. PATIENTS AND METHODS: Patient, tumor, and treatment characteristics, as well as clinical outcomes of all consecutively treated patients with raltitrexed at the Royal Marsden Hospital between October 1998 and July 2011 were examined...
September 29, 2018: Clinical Colorectal Cancer
Seán Fitzgerald, Julie-Ann O'Reilly, Erin Wilson, Ann Joyce, Richard Farrell, Dermot Kenny, Elaine Williamson Kay, Jenny Fitzgerald, Barry Byrne, Gregor Stefan Kijanka, Richard O'Kennedy
INTRODUCTION: Colorectal cancer is a major public health issue, with incidences continuing to rise owing to the growing and aging world population. Current screening strategies for colorectal cancer diagnosis suffer from various limitations, including invasiveness and poor uptake. Consequently, there is an unmet clinical need for a minimally invasive, sensitive, and specific method for detecting the presence of colorectal cancer and pre-malignant lesions. PATIENTS AND METHODS: An indirect enzyme-linked immunosorbent assay was used to measure the primary (IgM) and secondary (IgG) adaptive humoral immune responses to a panel of previously identified cancer antigens in the sera of normal and adenoma samples, and sera from patients with colorectal cancer...
September 27, 2018: Clinical Colorectal Cancer
Omar Abdel-Rahman
BACKGROUND: Baseline albumin-bilirubin (ALBI) score has been shown to be a reliable prognostic predictor among patients with hepatocellular carcinoma. The current study aims at evaluating its prognostic impact among patients with colorectal liver metastases treated with first-line systemic therapy. MATERIALS AND METHODS: Through the Project Data Sphere portal, de-identified clinical trial datasets of 2 clinical trials (NCT00115765; PACCE [Panitumumab Advanced Colorectal Cancer Evaluation Study] trial) and (NCT00364013; PRIME [Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy] trial) were downloaded...
September 27, 2018: Clinical Colorectal Cancer
Jacqueline Wyss, Bastian Dislich, Viktor H Koelzer, José A Galván, Heather Dawson, Marion Hädrich, Daniel Inderbitzin, Alessandro Lugli, Inti Zlobec, Martin D Berger
INTRODUCTION: The programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) axis plays an important role in controlling immune suppression by down-regulating T effector cell activities, enabling tumor cells to escape from the host's antitumor immunsurveillance. While only a small part of colon cancer cells express PD-L1, we sought to evaluate the differential impact of stromal and epithelial PD-L1 expression of primary tumors and liver metastasis on overall survival (OS) in colon cancer patients...
September 21, 2018: Clinical Colorectal Cancer
Sebastian Mondaca, Walid K Chatila, David Bates, Jaclyn F Hechtman, Andrea Cercek, Neil H Segal, Zsofia K Stadler, Anna M Varghese, Ritika Kundra, Marinela Capanu, Jinru Shia, Nikolaus Schultz, Leonard Saltz, Rona Yaeger
BACKGROUND: Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC. PATIENTS AND METHODS: We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy - essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin - in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers...
September 21, 2018: Clinical Colorectal Cancer
Jeremy D Shapiro, Subotheni Thavaneswaran, Craig R Underhill, Kristy P Robledo, Christos S Karapetis, Fiona L Day, Louise M Nott, Michael Jefford, Lorraine A Chantrill, Nick Pavlakis, Niall C Tebbutt, Timothy J Price, Mustafa Khasraw, Guy A Van Hazel, Paul M Waring, Sabine Tejpar, John Simes, Val J Gebski, Jayesh Desai, Eva Segelov
BACKGROUND: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation (ICECREAM) study assessed the efficacy of cetuximab monotherapy compared with cetuximab combined with chemotherapy for quadruple wild-type (KRAS, NRAS, BRAF, or P13KCA exon 20) metastatic colorectal cancer. PATIENTS AND METHODS: Patients were enrolled in an open-label, multicenter, phase II trial and randomly assigned to cetuximab 400 mg/m2 , then 250 mg/m2 cetuximab weekly, with or without irinotecan 180 mg/m2 every 2 weeks...
December 2018: Clinical Colorectal Cancer
Yu Sunakawa, Dongyun Yang, Shu Cao, Wu Zhang, Miriana Moran, Stephanie H Astrow, Jack Hsiang, Craig Stephens, Akihito Tsuji, Takehiro Takahashi, Hiroaki Tanioka, Yuji Negoro, Akinori Takagane, Satoshi Tani, Tatsuro Yamaguchi, Tetsuya Eto, Masashi Fujii, Wataru Ichikawa, Heinz-Josef Lenz
BACKGROUND: Few clinical studies have investigated the association between neutrophil-lymphocyte ratio (NLR) and treatment with cetuximab-based chemotherapy in metastatic colorectal cancer (mCRC). The NLR may reflect immune cells modulating specific cytokine signals in the tumor microenvironment; however, which immune-related genes affect the NLR remain unclear. PATIENTS AND METHODS: In 77 patients with KRAS exon2 wild-type mCRC from prospective trials of first-line chemotherapy with cetuximab, expression levels of 354 immune-related genes were measured in tissue samples obtained from all patients by the HTG EdgeSeq Oncology Biomarker Panel...
December 2018: Clinical Colorectal Cancer
Christopher J Bakkenist, James J Lee, John C Schmitz
No abstract text is available yet for this article.
September 13, 2018: Clinical Colorectal Cancer
Aabra Ahmed, Ahmed Tahseen, Elizabeth England, Katrine Wolfe, Michael Simhachalam, Travis Homan, Jenna Sitenga, Ryan W Walters, Peter T Silberstein
BACKGROUND: Colon cancer is the third most frequent cancer diagnosis, and primary payer status has been shown to be associated with treatment modalities and survival in cancer patients. The goal of our study was to determine the between-insurance differences in survival in patients with clinical stage III colon cancer using data from the National Cancer Database (NCDB). MATERIALS AND METHODS: We identified 130,998 patients with clinical stage III colon cancer in the NCDB diagnosed from 2004 to 2012...
September 13, 2018: Clinical Colorectal Cancer
Ieva Kurilova, Regina G H Beets-Tan, Jessica Flynn, Mithat Gönen, Gary Ulaner, Elena N Petre, F Edward Boas, Etay Ziv, Hooman Yarmohammadi, Elisabeth G Klompenhouwer, Andrea Cercek, Nancy A Kemeny, Constantinos T Sofocleous
INTRODUCTION: The purpose of this study was to identify predictors of overall (OS) and liver progression-free survival (LPFS) following Yttrium-90 radioembolization (RAE) of heavily pretreated patients with colorectal cancer liver metastases (CLM), as well as to create and validate a predictive nomogram for OS. MATERIALS AND METHODS: Metabolic, anatomic, laboratory, pathologic, genetic, primary disease, and procedure-related factors, as well as pre- and post-RAE therapies in 103 patients with CLM treated with RAE from September 15, 2009 to March 21, 2017 were analyzed...
September 13, 2018: Clinical Colorectal Cancer
Manuela Vasconcelos Castro Sales, Claudia K Suemoto, Daniel Apolinario, ValeriaT Serrao, Celi S Andrade, David M Conceição, Edson Amaro, Brian Alvarez Ribeiro de Melo, Rachel P Riechelmann
PURPOSE: Chemotherapy-related cognitive impairment can occur in cancer survivors after treatment, especially those patients who have undergone chemotherapy for breast cancer. The frequency and to what extent such toxicity develops in colorectal cancer (CRC) survivors is unknown. The present prospective study evaluated the effects of adjuvant chemotherapy on the cognitive performance of patients with localized CRC compared with a control group who had not undergone chemotherapy. PATIENTS AND METHODS: Consecutive patients with localized stage II and III CRC completed neuropsychological assessments, self-reported cognitive complaint questionnaires, and depressive symptom evaluations before starting fluoropyrimidine-based adjuvant chemotherapy and after 12 months...
September 13, 2018: Clinical Colorectal Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"